期刊
NUCLEAR MEDICINE AND BIOLOGY
卷 92, 期 -, 页码 156-170出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.nucmedbio.2020.06.007
关键词
Immuno-PET; Antibodies PET probes; Peptidic PET probes; Nucleic adds PET probes; Radiolabeling; Chelator development; Pharmacokinetics; Drug delivery system (DDS)
资金
- consignment expense for the Japan Advanced Molecular Imaging Program (JAMP) from the Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japanese Government
- Japan Agency for Medical Research and Development (AMED) [JP20cm0106201]
Recent progress in radiolabeling of macro- and middle-sized molecular probes has expanded the possibilities of using PET molecular imaging in drug development and therapeutic evaluation, improving the accuracy of target recognition and patient selection. Current focus is on immuno-PET and related technologies.
Recent progress in radiolabeling of macro- and middle-sized molecular probes has been extending possibilities to use PET molecular imaging for dynamic application to drug development and therapeutic evaluation. Theranostics concept also accelerated the use of macro- and middle-sized molecular probes for sharpening the contrast of proper target recognition even the cellular types/subtypes and proper selection of the patients who should be treated by the same molecules recognition. Here, brief summary of the present status of immuno-PET, and then further development of advanced technologies related to immuno-PET, peptidic PET probes, and nucleic acids PET probes are described. (C) 2020 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据